Circulation. 2004;109:2068-2073
Published online before print April 19, 2004, doi: 10.1161/01.CIR.0000127578.21885.3E
Published online before print April 19, 2004, doi: 10.1161/01.CIR.0000127578.21885.3E
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:2068-2073.)
© 2004 American Heart Association, Inc.
Clinical Investigation and Reports |
Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
From the Division of Pharmacoepidemiology and Pharmacoeconomics (D.H.S., S.S., R.J.G., Y.K., R.L., H.M., J.A.) and Division of Rheumatology, Immunology, and Allergy (D.H.S.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.
Correspondence to Daniel H. Solomon, MD, MPH, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120. E-mail dhsolomon{at}partners.org
Received October 7, 2003; revision received January 22, 2004; accepted February 5, 2004.
Background— Although cyclooxygenase-2 inhibitors (coxibs) were developed to cause less gastrointestinal hemorrhage than nonselective nonsteroidal antiinflammatory drugs (NSAIDs), there has been concern about their cardiovascular safety. We studied the relative risk of acute myocardial infarction (AMI) among users of celecoxib, rofecoxib, and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit.
Methods and Results— We conducted a matched case-control study of 54 475 patients 65 years of age or older who received their medications through 2 state-sponsored pharmaceutical benefits programs in the United States. All healthcare use encounters were examined to identify hospitalizations for AMI. Each of the 10 895 cases of AMI was matched to 4 controls on the basis of age, gender, and the month of index date. We constructed matched logistic regression models including indicators for patient demographics, healthcare use, medication use, and cardiovascular risk factors to assess the relative risk of AMI in patients who used rofecoxib compared with persons taking no NSAID, taking celecoxib, or taking NSAIDs. Current use of rofecoxib was associated with an elevated relative risk of AMI compared with celecoxib (odds ratio [OR], 1.24; 95% CI, 1.05 to 1.46; P=0.011) and with no NSAID (OR, 1.14; 95% CI, 1.00 to 1.31; P=0.054). The adjusted relative risk of AMI was also elevated in dose-specific comparisons: rofecoxib 
25 mg versus celecoxib 200 mg (OR, 1.21; 95% CI, 1.01 to 1.44; P=0.036) and rofecoxib >25 mg versus celecoxib >200 mg (OR, 1.70; 95% CI, 1.07 to 2.71; P=0.026). The adjusted relative risks of AMI associated with rofecoxib use of 1 to 30 days (OR, 1.40; 95% CI, 1.12 to 1.75; P=0.005) and 31 to 90 days (OR, 1.38; 95% CI, 1.11 to 1.72; P=0.003) were higher than >90 days (OR, 0.96; 95% CI, 0.72 to 1.25; P=0.8) compared with celecoxib use of similar duration. Celecoxib was not associated with an increased relative risk of AMI in these comparisons.
Conclusions— In this study, current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use. Dosages of rofecoxib >25 mg were associated with a higher risk than dosages 25 mg. The risk was elevated in the first 90 days of use but not thereafter.
Key Words: cyclooxygenase inhibitors • myocardial infarction • aging
This article has been cited by other articles:
 |
|
 |
|
  T C. Cheetham, G. Levy, F. Niu, and F. Bixler Gastrointestinal Safety of Nonsteroidal Antiinflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors in Patients on Warfarin Ann. Pharmacother., November 1, 2009; 43(11): 1765 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Nicholson, B. Vaa, C. Hesse, J. H. Eisenach, and M. J. Joyner Aging Is Associated With Reduced Prostacyclin-Mediated Dilation in the Human Forearm Hypertension, June 1, 2009; 53(6): 973 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa Statistical methods in pharmacoepidemiology: advances and challenges Statistical Methods in Medical Research, February 1, 2009; 18(1): 3 - 6. [PDF]
|
|
|
|
 |
|
 A. Kulik, M. A. Brookhart, R. Levin, M. Ruel, D. H. Solomon, and N. K. Choudhry Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery Circulation, October 28, 2008; 118(18): 1785 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, May 13, 2008; 117(19): 2544 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Solomon, J. Wittes, P. V. Finn, R. Fowler, J. Viner, M. M. Bertagnolli, N. Arber, B. Levin, C. L. Meinert, B. Martin, et al. Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis Circulation, April 22, 2008; 117(16): 2104 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jacobshagen, M. Gruber, N. Teucher, A. G. Schmidt, B. W. Unsold, K. Toischer, P. Nguyen Van, L. S. Maier, H. Kogler, and G. Hasenfuss Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction Eur J Heart Fail, April 1, 2008; 10(4): 334 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T P van Staa, L Smeeth, I Persson, J Parkinson, and H G M Leufkens What is the harm-benefit ratio of Cox-2 inhibitors? Int. J. Epidemiol., April 1, 2008; 37(2): 405 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Hennekens and S. Borzak Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 41 - 50. [Abstract] [PDF]
|
|
|
|
 |
|
 P. I. Sidiropoulos, G. Hatemi, I.-H. Song, J. Avouac, E. Collantes, V. Hamuryudan, M. Herold, T. K. Kvien, H. Mielants, J. M. Mendoza, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists Rheumatology, March 1, 2008; 47(3): 355 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Joshi, R. Gertler, and R. Fricker Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs Anesth. Analg., December 1, 2007; 105(6): 1793 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kulik, R. Levin, M. Ruel, T. G. Mesana, D. H. Solomon, and N. K. Choudhry Patterns and predictors of statin use after coronary artery bypass graft surgery. J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 932 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Scott, G H Kingsley, C M Smith, E H Choy, and D L Scott Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials Ann Rheum Dis, October 1, 2007; 66(10): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rother, B. J Lavins, W. Kneer, K. Lehnhardt, E. J Seidel, and S. Mazgareanu Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial Ann Rheum Dis, September 1, 2007; 66(9): 1178 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K Choudhry, R. Levin, and W. C Winkelmayer Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice Heart, August 1, 2007; 93(8): 945 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rahme, M. Bardou, K. Dasgupta, Y. Toubouti, J. Ghosn, and A. N. Barkun Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study Rheumatology, February 1, 2007; 46(2): 265 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Jugdutt Cyclooxygenase Inhibition and Adverse Remodeling During Healing After Myocardial Infarction Circulation, January 23, 2007; 115(3): 288 - 291. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Schneider, L. E. Levesque, B. Zhang, T. Hutchinson, and J. M. Brophy Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-based, Nested Case-Control Analysis Am. J. Epidemiol., November 1, 2006; 164(9): 881 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. McGettigan and D. Henry Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2 JAMA, October 4, 2006; 296(13): 1633 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chaiamnuay, J. J. Allison, and J. R. Curtis Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1837 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oitate, T. Hirota, K. Koyama, S.-i. Inoue, K. Kawai, and T. Ikeda COVALENT BINDING OF RADIOACTIVITY FROM [14C]ROFECOXIB, BUT NOT [14C]CELECOXIB OR [14C]CS-706, TO THE ARTERIAL ELASTIN OF RATS Drug Metab. Dispos., August 1, 2006; 34(8): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Helin-Salmivaara, A. Virtanen, R. Vesalainen, J. M. Gronroos, T. Klaukka, J. E. Idanpaan-Heikkila, and R. Huupponen NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland Eur. Heart J., July 2, 2006; 27(14): 1657 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Gislason, S. Jacobsen, J. N. Rasmussen, S. Rasmussen, P. Buch, J. Friberg, T. K. Schramm, S. Z. Abildstrom, L. Kober, M. Madsen, et al. Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction Circulation, June 27, 2006; 113(25): 2906 - 2913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Levesque, J. M. Brophy, and B. Zhang Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors Can. Med. Assoc. J., May 23, 2006; 174(11): 1563 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Elliott, L. Hooper, K. Payne, T. J. Brown, C. Roberts, and D. Symmons Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology, May 1, 2006; 45(5): 606 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andersohn, S. Suissa, and E. Garbe Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction Circulation, April 25, 2006; 113(16): 1950 - 1957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Caldwell, S. Aldington, M. Weatherall, P. Shirtcliffe, and R. Beasley Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med, March 1, 2006; 99(3): 132 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-p. Zhao, P. Deng, H.-g. Huang, Z.-m. Xu, H.-y. Dai, S.-c. Hong, J. Yang, and H.-n. Zhou Expression of COX-2 mRNA in Peripheral Blood Monocytes from Patients with Acute Myocardial Infarction and Its Significance Clin. Chem., November 1, 2005; 51(11): 2170 - 2173. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Brophy, L. E. Levesque, and B. Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors Ann Intern Med, October 18, 2005; 143(8): 617 - 618. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Pijak, I. Huzicka, and F. Gazdik Coxibs and cardiovascular risk Can. Med. Assoc. J., October 11, 2005; 173(8): 852 - 852. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Bonvini, T. Hendiri, and E. Camenzind Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I27 - I36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Jones and I. Power Editorial I: Postoperative NSAIDs and COX-2 inhibitors: cardiovascular risks and benefits Br. J. Anaesth., September 1, 2005; 95(3): 281 - 284. [Full Text] [PDF]
|
|
|
|
|
|
M. Hermann, H. Krum, and F. Ruschitzka To the Heart of the Matter: Coxibs, Smoking, and Cardiovascular Risk Circulation, August 16, 2005; 112(7): 941 - 945. [Full Text] [PDF]
|
|
|
|
|
|
D. Pratico and J.-M. Dogne Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine Circulation, August 16, 2005; 112(7): 1073 - 1079. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, D. DeMets, and J. Loscalzo Cyclooxygenase Inhibition and Cardiovascular Risk Circulation, August 2, 2005; 112(5): 759 - 770. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Konstantinopoulos and D. F. Lehmann The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding J. Clin. Pharmacol., July 1, 2005; 45(7): 742 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S C. Jones Relative Thromboembolic Risks Associated with COX-2 Inhibitors Ann. Pharmacother., July 1, 2005; 39(7): 1249 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Brophy, S. D. Solomon, J. Wittes, J. McMurray, the APC Study Cardiovascular Safety Committee and, B. M. Psaty, and C. D. Furberg Cardiovascular Risk Associated with Celecoxib N. Engl. J. Med., June 23, 2005; 352(25): 2648 - 2650. [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Berg and P. E. Scherer Adipose Tissue, Inflammation, and Cardiovascular Disease Circ. Res., May 13, 2005; 96(9): 939 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Johnsen, H. Larsson, R. E. Tarone, J. K. McLaughlin, B. Norgard, S. Friis, and H. T. Sorensen Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study Arch Intern Med, May 9, 2005; 165(9): 978 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Romanovsky Vioxx, Celebrex, Bextra....Do we have a new target for anti-inflammatory and antipyretic therapy? Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2005; 288(5): R1098 - R1099. [Full Text] [PDF]
|
|
|
|
|
|
J. Fredy, D. A Diggins Jr, and G. B Morrill Blood Pressure in Native Americans Switched from Celecoxib to Rofecoxib Ann. Pharmacother., May 1, 2005; 39(5): 797 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D Martina, K. S Vesta, and T. L Ripley Etoricoxib: A Highly Selective COX-2 Inhibitor Ann. Pharmacother., May 1, 2005; 39(5): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown and R. N. DuBois COX-2: A Molecular Target for Colorectal Cancer Prevention J. Clin. Oncol., April 20, 2005; 23(12): 2840 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Levesque, J. M. Brophy, and B. Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Ann Intern Med, April 5, 2005; 142(7): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steffel, M. Hermann, H. Greutert, S. Gay, T. F. Luscher, F. Ruschitzka, and F. C. Tanner Celecoxib Decreases Endothelial Tissue Factor Expression Through Inhibition of c-Jun Terminal NH2 Kinase Phosphorylation Circulation, April 5, 2005; 111(13): 1685 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Rawson, P. Nourjah, S. C Grosser, and D. J Graham Factors Associated with Celecoxib and Rofecoxib Utilization Ann. Pharmacother., April 1, 2005; 39(4): 597 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Solomon, J. J.V. McMurray, M. A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W. F. Anderson, A. Zauber, E. Hawk, M. Bertagnolli, et al. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention N. Engl. J. Med., March 17, 2005; 352(11): 1071 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Bresalier, R. S. Sandler, H. Quan, J. A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial N. Engl. J. Med., March 17, 2005; 352(11): 1092 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bhattacharyya and R. M. Smith Cardiovascular Risks of Coxibs: The Orthopaedic Perspective J. Bone Joint Surg. Am., February 1, 2005; 87(2): 245 - 246. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kimmel, J. A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B. L. Strom Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction Ann Intern Med, February 1, 2005; 142(3): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Finckh and M. D. Aronson Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now Ann Intern Med, February 1, 2005; 142(3): 212 - 214. [Full Text] [PDF]
|
|
|
|
|
|
M. Hermann, S. Shaw, E. Kiss, G. Camici, N. Buhler, R. Chenevard, T. F. Luscher, H. J. Grone, and F. Ruschitzka Selective COX-2 Inhibitors and Renal Injury in Salt-Sensitive Hypertension Hypertension, February 1, 2005; 45(2): 193 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Solomon and J. Avorn Coxibs, Science, and the Public Trust Arch Intern Med, January 24, 2005; 165(2): 158 - 160. [Full Text] [PDF]
|
|
|
|
|
|
F. T. Shaya, S. W. Blume, C. M. Blanchette, M. R. Weir, and C. D. Mullins Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: An Observational Study of a Medicaid Population Arch Intern Med, January 24, 2005; 165(2): 181 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Topol Arthritis Medicines and Cardiovascular Events--"House of Coxibs" JAMA, January 19, 2005; 293(3): 366 - 368. [Full Text] [PDF]
|
|
|
|
 |
|
 Taking stock of coxibs DTB, January 1, 2005; 43(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Grover, L. Coupal, and H. Zowall Treating Osteoarthritis With Cyclooxygenase-2-Specific Inhibitors: What Are the Benefits of Avoiding Blood Pressure Destabilization? Hypertension, January 1, 2005; 45(1): 92 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. White Hypertension Associated With Therapies to Treat Arthritis and Pain Hypertension, August 1, 2004; 44(2): 123 - 124. [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, May 22, 2004; 328(7450): 1268 - 1268. [Full Text] [PDF]
|
|
|
|
|
|
R. SoRelle Cardiovascular News Circulation, May 4, 2004; 109(17): e9039 - e9040. [Full Text]
|
|
|
|
|
|
L. E. Levesque, J. M. Brophy, and B. Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Ann Intern Med, April 5, 2005; 142(7): 481 - 489. [Abstract] [Full Text] [PDF]
|
|